ENDRA Life Sciences Q4 net loss $4.2M, cash burn cut, pivots to GLP-1 metabolic health

ENDRA Life Sciences Inc.

Q4 2024 net loss $4.2M ($1.5M in Q4 2023) includes $2.3M non-cash inventory charge; full-year net loss $11.5M.
Cash used in operations Q4 2024 $1.5M, down 32% YoY; expects ~$0.35M/month burn in Q2/Q3 2025.
Cash and equivalents $3.2M at Dec 31, 2024; prior to pivot, runway limited given burn rate.
New strategic direction: TAEUS as biomarker for monitoring GLP-1 drug patients, targeting pharma, concierge, primary care.
Planned De Novo pivotal trial: multi-center, ~250 subjects, hypothesis-driven, with FDA pre-submission alignment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.